ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

House Committee To Examine Personal Genetic Test Kits

May 21, 2010

Health Association Oppose U.S. Trade Policy On Tobacco Exports; Recommend Restrictions

August 25, 1989

DCPC Advisors Okay Minority Based CCOPs, RFA In Native Americans

January 15, 1993

NCI-Funded Modelers Accurately Predicted Outcome Of Lung Cancer Screening Trial

November 26, 2010

Ontak Approved For Lymphoma

October 31, 2008

Conversation with Walter Curran – Proton Therapy: What’s Known and What’s Not

October 25, 2013